Table 3.
Serious adverse events from CVOTs of GLP-1RA and SGLT2i in type 2 diabetes mellitus
| Adverse Event | Drug Class | Number Studied | RR | RD | NNH |
|---|---|---|---|---|---|
| Genital infections in women | SGLT2i | 13 551 | 4.07 (3.41, 4.86)*** | 0.07 (0.06, 0.08)*** | 13 |
| Amputations | SGLT2i | 38 723 | 1.19 (0.92, 1.55) | 0.004 (0.001, 0.007) | 265 |
| Volume depletion | SGLT2i | 38 723 | 1.04 (0.96, 1.14) | 0.002 (-0.002, 0.007) | 472 |
| Fractures | SGLT2i | 38 723 | 1.01 (0.93, 1.11) | 0.0008 (-0.0035, 0.0051) | 1250 |
| Diabetic ketoacidosis | SGLT2i | 38 723 | 2.60 (1.54, 4.40)*** | 0.0017 (0.0008, 0.0026)*** | 595 |
| Urinary tract infections | SGLT2i | 38 723 | 1.00 (0.92, 1.10) | 0.000 (-0.004, 0.005) | N/A |
| GI intolerance | GLP-1RA | 46 451 | 2.65 (1.36, 5.14)** | 0.029 (0.011, 0.046)*** | 35 |
| Gallstone/gallbladder disease | GLP-1RA | 36 640 | 1.24 (1.02, 1.52)* | 0.005 (-0.001, 0.011) | 200 |
| Pancreatitis | GLP-1RA | 46 451 | 1.08 (0.79, 1.48) | 0.00026 (0.00079, 0.00132) | 3846 |
Data for rr and rd are presented as mean (95% CI) and mean (standard deviation), respectively. Bolded text highlights significant differences of drug versus placebo.
*P < 0.05.
**P < 0.01.
***P < 0.001.